Literature DB >> 33831560

Structure activity relationship of 3-nitro-2-(trifluoromethyl)-2H-chromene derivatives as P2Y6 receptor antagonists.

Young-Hwan Jung1, Shanu Jain1, Varun Gopinatth1, Ngan B Phung1, Zhan-Guo Gao1, Kenneth A Jacobson2.   

Abstract

Various 6-alkynyl analogues of a known 3-nitro-2-(trifluoromethyl)-2H-chromene antagonist 3 of the Gq-coupled P2Y6 receptor (P2Y6R) were synthesized using a Sonogashira reaction to replace a 6-iodo group. The analogues were tested in a functional assay consisting of inhibition of calcium mobilization in P2Y6R-expressing astrocytoma cells elicited by native P2Y6R agonist UDP. 6-Ethynyl and 6-cyano groups were installed, and the alkynes were extended through both alkyl and aryl spacers. The most potent antagonists, with IC50 of ~1 µM, were found to be trialkylsilyl-ethynyl 7 and 8 (3-5 fold greater affinity than reference 3), t-butyl prop-2-yn-1-ylcarbamate 14 and p-carboxyphenyl-ethynyl 16 derivatives, and 3 and 8 displayed surmountable antagonism of UDP-induced production of inositol phosphates. Other chain-extended terminal carboxylate derivatives were less potent than the corresponding methyl ester derivatives. Thus, the 6 position in this chromene series is suitable for derivatization with flexibility of substitution, even with sterically extended chains, without losing P2Y6R affinity. However, a 3-carboxylic acid or 3-ester substitution did not serve as a nitro bioisostere, as the affinity was eliminated. These compounds provide additional ligand tools for the underexplored P2Y6R, which is a target for inflammatory, neurodegenerative and metabolic diseases. Published by Elsevier Ltd.

Entities:  

Keywords:  Antagonist; Calcium mobilization; P2Y receptor; Purinergic; Structure activity relationship

Mesh:

Substances:

Year:  2021        PMID: 33831560      PMCID: PMC8240625          DOI: 10.1016/j.bmcl.2021.128008

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.940


  38 in total

1.  Pyrimidine ribonucleotides with enhanced selectivity as P2Y(6) receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5'-triphosphate gamma-ester modifications.

Authors:  Hiroshi Maruoka; Matthew O Barrett; Hyojin Ko; Dilip K Tosh; Artem Melman; Lauren E Burianek; Ramachandran Balasubramanian; Barkin Berk; Stefano Costanzi; T Kendall Harden; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2010-06-10       Impact factor: 7.446

2.  UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis.

Authors:  Schuichi Koizumi; Yukari Shigemoto-Mogami; Kaoru Nasu-Tada; Yoichi Shinozaki; Keiko Ohsawa; Makoto Tsuda; Bhalchandra V Joshi; Kenneth A Jacobson; Shinichi Kohsaka; Kazuhide Inoue
Journal:  Nature       Date:  2007-04-04       Impact factor: 49.962

3.  Design and synthesis of new bicyclic diketopiperazines as scaffolds for receptor probes of structurally diverse functionality.

Authors:  Pedro Besada; Liaman Mamedova; Craig J Thomas; Stefano Costanzi; Kenneth A Jacobson
Journal:  Org Biomol Chem       Date:  2005-04-21       Impact factor: 3.876

4.  Lack of effect of a P2Y6 receptor antagonist on neuropathic pain behavior in mice.

Authors:  Katharina Martina Janice Syhr; Wiebke Kallenborn-Gerhardt; Ruirui Lu; Katrin Olbrich; Katja Schmitz; Julia Männich; Nerea Ferreiros-Bouzas; Gerd Geisslinger; Ellen Niederberger; Achim Schmidtko
Journal:  Pharmacol Biochem Behav       Date:  2014-07-18       Impact factor: 3.533

5.  Exacerbated intestinal inflammation in P2Y6 deficient mice is associated with Th17 activation.

Authors:  Mabrouka Salem; Mohammed-Amine El Azreq; Julie Pelletier; Bernard Robaye; Fawzi Aoudjit; Jean Sévigny
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-07-02       Impact factor: 5.187

6.  Distinct Signaling Patterns of Allosteric Antagonism at the P2Y1 Receptor.

Authors:  Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Mol Pharmacol       Date:  2017-09-01       Impact factor: 4.436

7.  Synthesis and structure-activity relationship of uracil nucleotide derivatives towards the identification of human P2Y6 receptor antagonists.

Authors:  Diana Meltzer; Ophir Ethan; Guillaume Arguin; Yael Nadel; Ortal Danino; Joanna Lecka; Jean Sévigny; Fernand-Pierre Gendron; Bilha Fischer
Journal:  Bioorg Med Chem       Date:  2015-07-11       Impact factor: 3.641

8.  Nitro-Group-Containing Drugs.

Authors:  Kunal Nepali; Hsueh-Yun Lee; Jing-Ping Liou
Journal:  J Med Chem       Date:  2018-11-01       Impact factor: 7.446

9.  NTPDase8 protects mice from intestinal inflammation by limiting P2Y6 receptor activation: identification of a new pathway of inflammation for the potential treatment of IBD.

Authors:  Mabrouka Salem; Joanna Lecka; Julie Pelletier; Danielle Gomes Marconato; Aline Dumas; Luc Vallières; Gaetan Brochu; Bernard Robaye; Christian Jobin; Jean Sévigny
Journal:  Gut       Date:  2021-01-15       Impact factor: 23.059

Review 10.  Update of P2Y receptor pharmacology: IUPHAR Review 27.

Authors:  Kenneth A Jacobson; Esmerilda G Delicado; Christian Gachet; Charles Kennedy; Ivar von Kügelgen; Beibei Li; M Teresa Miras-Portugal; Ivana Novak; Torsten Schöneberg; Raquel Perez-Sen; Doreen Thor; Beili Wu; Zhenlin Yang; Christa E Müller
Journal:  Br J Pharmacol       Date:  2020-04-06       Impact factor: 9.473

View more
  3 in total

Review 1.  Adipocyte purinergic receptors activated by uracil nucleotides as obesity and type 2 diabetes targets.

Authors:  Shanu Jain; Kenneth A Jacobson
Journal:  Curr Opin Pharmacol       Date:  2022-02-26       Impact factor: 5.547

Review 2.  Purinergic Signaling in Liver Pathophysiology.

Authors:  Shanu Jain; Kenneth A Jacobson
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-11       Impact factor: 5.555

3.  Synthesis and pharmacological characterization of multiply substituted 2H-chromene derivatives as P2Y6 receptor antagonists.

Authors:  Young-Hwan Jung; Qasim Shah; Sarah A Lewicki; Asmita Pramanik; Varun Gopinatth; Julie Pelletier; Jean Sévigny; Jamshed Iqbal; Kenneth A Jacobson
Journal:  Bioorg Med Chem Lett       Date:  2022-09-08       Impact factor: 2.940

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.